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Weight and height z-scores improve after
initiating ART among HIV-infected children in
rural Zambia: a cohort study
Catherine G Sutcliffe1*, Janneke H van Dijk2, Bornface Munsanje2, Francis Hamangaba2, Pamela Sinywimaanzi2,
Philip E Thuma2, William J Moss1

Abstract
Background: Deficits in growth observed in HIV-infected children in resource-poor settings can be reversed with
antiretroviral treatment (ART). However, many of the studies have been conducted in urban areas with older
pediatric populations. This study was undertaken to evaluate growth patterns after ART initiation in a young
pediatric population in rural Zambia with a high prevalence of undernutrition.
Methods: Between 2007 and 2009, 193 HIV-infected children were enrolled in a cohort study in Macha, Zambia.
Children were evaluated every 3 months, at which time a questionnaire was administered, height and weight were
measured, and blood specimens were collected. Weight- and height-for-age z-scores were constructed from WHO
growth standards. All children receiving ART at enrollment or initiating ART during the study were included in this
analysis. Linear mixed effects models were used to model trajectories of weight and height-for-age z-scores.
Results: A high proportion of study children were underweight (59%) and stunted (72%) at treatment initiation.
Improvements in both weight- and height-for-age z-scores were observed, with weight-for-age z-scores increasing
during the first 6 months of treatment and then stabilizing, and height-for-age z-scores increasing consistently over
time. Trajectories of weight-for-age z-scores differed by underweight status at treatment initiation, with children
who were underweight experiencing greater increases in z-scores in the first 6 months of treatment. Trajectories of
height-for-age z-scores differed by age, with children older than 5 years of age experiencing smaller increases over
time.
Conclusions: Some of the effects of HIV on growth were reversed with ART initiation, although a high proportion
of children remained underweight and stunted after two years of treatment. Partnerships between treatment and
nutrition programs should be explored so that HIV-infected children can receive optimal nutritional support.

Background
Children in sub-Saharan Africa have high levels of
undernutrition, exhibiting lower weight- and height-forage than children in high resource settings. Both of
these conditions are exacerbated by HIV infection [1-4],
and can be used to determine disease status and monitor treatment response [5]. As implementation of antiretroviral treatment (ART) programs in sub-Saharan
Africa has increased [6], many HIV-infected children are
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1
Department of Epidemiology, Bloomberg School of Public Health, Johns
Hopkins University, Baltimore, MD, USA
Full list of author information is available at the end of the article

benefitting from treatment and are experiencing reductions in morbidity and mortality. Several studies have
shown that many of the deficits in growth due to HIV
infection are reversed with ART, with children exhibiting consistent improvements in weight-for-age [7-19].
Some studies, but not all [12,13,17], have also reported
improvements in height-for-age [7-10,14,16,18,19].
Gains in weight have been found to correlate with treatment response [19].
Many of these studies have been conducted in urban
areas, where food security tends to be higher and levels
of undernutrition lower than in surrounding rural areas
[20]. In addition, many of these studies were conducted
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in the first years of program implementation when the
majority of children initiating ART were older [21].
Both age [11] and level of undernutrition at treatment
initiation [7] have the potential to impact growth trajectories and the effect of ART. Consequently, this study
was undertaken to evaluate growth after ART initiation
in a young pediatric population in rural Zambia and
identify characteristics at ART initiation that influence
growth trajectories.

Methods
Study setting and population

The study was conducted at Macha Hospital in a rural
area of Southern Province, Zambia. The study setting
and population have been described in detail elsewhere
[22]. Briefly, Macha Hospital is a district-level referral
hospital administered by the Zambian Brethren in Christ
Church. Since 2005, Macha Hospital has provided care
to over 6000 HIV-infected adults and children through
the Government of Zambia’s antiretroviral treatment
program, with additional support from the President’s
Emergency Plan for AIDS Relief (PEPFAR) through the
non-governmental organization, AidsRelief.
Children with a positive HIV serologic test are
referred to the clinic from voluntary counseling and
testing programs, outpatient clinics and rural health
centers. Early infant diagnosis has been available since
February 2008. Clinical care is provided without charge
by medical doctors and clinical officers, and adherence
counseling by nurses and trained counselors. ART is
initiated according to WHO guidelines [23,24]. The
first-line antiretroviral treatment regimen consists of
two nucleoside reverse transcriptase inhibitors (lamivudine (3TC) plus zidovudine (AZT) or stavudine (D4T)
or abacavir (ABC)) and a non-nucleoside reverse transcriptase inhibitor (efavirenz (EFV) or nevirapine
(NVP)). Pediatric and adult fixed dose combinations of
D4T and 3TC are available, as well as of D4T, 3TC and
NVP. High energy protein supplements are provided to
underweight children.
Study procedures

Beginning in September 2007, HIV-infected children
younger than 16 years seeking HIV care were eligible
for enrollment into a cohort study. Written informed
consent was obtained from parents or guardians and
assent was obtained from children 8-16 years of age.
Children were evaluated at study visits approximately
every three months, at which time a questionnaire was
administered, the child was examined and a blood specimen was obtained. At each visit CD4+ T-cell counts and
percentages were measured using the Guava Easy CD4
system (Guava Technologies, Inc., Hayward, CA). During each physical examination, height and weight were
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measured. For children who missed study visits, home
visits were attempted to ascertain their status. Information recorded before study enrollment was abstracted
from medical records. The study was approved by the
Ministry of Health in Zambia, the Research Ethics Committee of the University of Zambia and the Institutional
Review Board of the Johns Hopkins Bloomberg School
of Public Health.
For the present analysis, all children enrolled in the
study and receiving ART between September 2007 and
September 2009 were included. The study sample
included children already receiving ART at enrollment
and children initiating ART during the study period.
Statistical analysis

Data were entered in duplicate using EpiInfo (Centers
for Disease Control and Prevention) and analyses were
conducted in STATA, version 9 (StataCorp LP, College
Station, Texas). Weight-for-age z-scores (WAZ) among
children younger than 10 years of age and height-forage (HAZ) z-scores among all children were calculated
based on the WHO growth standards [25], and children
with z-scores below -2 were defined as underweight and
stunted, respectively. Severe immunodeficiency was
defined by CD4 + T-cell percentage according to the
WHO 2006 treatment guidelines [24].
WAZ and HAZ after ART initiation were assessed
among children with at least one post-ART measure.
Children were followed until they died, were lost to follow-up, or were administratively censored on September
30, 2009. Children who had not returned for at least 6
months were assumed lost to follow-up. For reporting
outcomes at specific time points after ART initiation,
measurements were aggregated to within 45 days. Treatment outcomes were evaluated using linear mixed
effects models with random intercept, exchangeable correlation structure and robust standard error estimation.
As changes in WAZ were not linear, a spline term was
added at 7.5 months, the upper window around the 6month measure. Covariates of interest included sex,
orphan status, education of the primary caregiver, age,
underweight, stunting and severe immunodeficiency at
ART initiation. Covariates found to be (p < 0.10) or
known to be associated with either outcome were
included in the models. Differences in trajectories of
WAZ and HAZ were assessed by each covariate of
interest.

Results
Characteristics of the study population at study
enrollment and ART initiation

Between September 2007 and 2009, 193 children
received ART, with 67 entering the study already receiving ART and 126 initiating ART after study enrollment.
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Children receiving ART at study enrollment entered a
median of 8.3 months (IQR: 2.3, 17.7) after initiating ART,
while treatment-naïve children initiated ART a median of
2.0 months (IQR: 0.9, 6.0) after study enrollment. The
median follow-up time in the study was 13.1 months (IQR:
5.1, 20.0). The median age was 3.0 years (IQR: 1.6, 6.9) at

study enrollment and 51.3% were male (Table 1). The
majority of children were cared for by a parent (77.5%) or
grandparent (13.6%). Sixty-three percent of primary caregivers had no high school education and 9.5% of children
were double orphans. Very few mothers (2.6%) had
received drugs to prevent mother-to-child transmission.

Table 1 Characteristics at study enrollment and ART initiation of HIV-infected children receiving antiretroviral therapy
Total
(n = 193)

Children receiving ART at study
enrollment (n = 67)

Children starting ART during study period p-value
(n = 126)

3.01 (1.62,
6.89)

4.25 (2.46, 8.61)

2.53 (1.27, 6.34)

Study enrollment
Median age in years (IQR)
<1 yr

24 (12.4)

2 (3.0)

22 (17.5)

1-1.9 yrs
2-4.9 yrs

38 (19.7)
66 (34.2)

8 (11.9)
29 (43.3)

30 (23.8)
37 (29.4)

5+ yrs

0.0005

65 (33.7)

28 (41.8)

37 (29.4)

0.002

99 (51.3)

43 (64.2)

56 (44.4)

0.009

5 (2.6)

0 (0.0)

5 (4.0)

0.24

Both alive

135 (71.1)

39 (60.9)

96 (76.2)

Mother died

19 (10.0)

7 (10.9)

12 (9.5)

Father died
Both died

18 (9.5)
18 (9.5)

8 (12.5)
10 (15.6)

10 (7.9)
8 (6.4)

Mother/father

148 (77.5)

48 (73.9)

100 (79.4)

Grandparent

26 (13.6)

11 (16.9)

15 (11.9)

Aunt/uncle

12 (6.3)

5 (7.7)

7 (5.6)

Other

5 (2.6)

1 (1.5)

4 (3.2)

Male sex
Mother received PMTCT (%)
Vital status of parents (%)

0.10

Primary caregiver (%)

0.55

Education of primary
caregiver (%)
None
Primary
Secondary
Higher

11 (6.3)

3 (5.3)

8 (6.8)

100 (57.1)
62 (35.4)

31 (54.4)
23 (40.4)

69 (58.5)
39 (33.1)

2 (1.1)

0 (0.0)

2 (1.7)

0.62

2.93 (1.66,
6.84)

3.07 (1.71, 7.91)

2.87 (1.60, 6.73)

0.33

ART initiation
Median age in years (IQR)
<1 yr

23 (11.9)

6 (9.0)

17 (13.5)

1-1.9 yrs

41 (21.2)

15 (22.4)

26 (20.6)

2-4.9 yrs

64 (33.2)

21 (31.3)

43 (34.1)

65 (33.7)
-2.30 (-3.46,
-1.37)

25 (37.3)
-2.55 (-3.92, -1.80)

40 (31.8)
-2.10 (-3.22, -1.26)

0.72
0.02

89 (58.9)
-3.15 (-4.30,
-1.91)
69 (71.9)

34 (70.8)
-4.86 (-6.26, -3.15)

55 (53.4)
-3.02 (-4.20, -1.90)

0.04
0.10

7 (87.5)

62 (70.5)

0.30

16.3 (11.5,
20.1)
95 (59.8)

13.6 (9.7, 16.6)

17.4 (12.9, 20.5)

0.01

26 (70.3)

69 (56.6)

0.14

5+ yrs
Median WAZ (IQR)a
Underweight
Median HAZ (IQR)
Stunted
Median CD4% (IQR)
Severe
immunodeficiency (%)b

ART: antiretroviral treatment; IQR: interquartile range; PMTCT: prevention of mother-to-child transmission; WAZ: weight for age z-score; HAZ: height for age zscore.
a
among children <10 years of age.
b
defined by age according to the 2006 WHO guidelines.
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treatment initiation to -1.3, -1.5, -1.4 and -1.7 at 6, 12,
18 and 24 months on ART, respectively (Figure 1A).
Consequently, the proportion of underweight children
decreased from 59.7% at treatment initiation to 28.8%,
35.3%, 26.5% and 45.0% at 6, 12, 18, and 24 months on
ART, respectively. Results of the crude longitudinal
models indicated that WAZ increased by 0.12 units per
month in the first 6 months of ART, and remained
stable thereafter (Table 2). Male sex, double orphan status and older age at ART initiation were significantly
associated with lower WAZ. Severe immunodeficiency
at ART initiation was marginally associated with lower
WAZ. Differing patterns of improvement were found
only by WAZ at ART initiation, with underweight children experiencing greater increases in WAZ in the first
6 months of ART.

The median age at ART initiation was 2.9 years (IQR: 1.7,
6.8). The median WAZ and HAZ at ART initiation were
-2.3 (IQR: -3.5, -1.4; 58.9% underweight) and -3.2 (IQR:
-4.3, -1.9; 71.9% stunted), respectively. The median CD4+
T-cell percentage at ART initiation was 16.3% (IQR: 11.5,
20.1; 59.8% severe immunodeficiency). Children who
entered the study already receiving ART were significantly
older and more likely to be male. In addition, they were
significantly more likely to be underweight and have a
lower CD4+ T-cell percentage at ART initiation.
The initial ART regimen was D4T/3TC/NVP for
40.5% of children. Other regimens included AZT/3TC/
EFV (24.3%), D4T/3TC/EFV (18.9%), and AZT/3TC/
NVP (13.5%). An additional three children received a
regimen including ABC (2.0%) and one child received a
regimen including emtricitabine and tenofovir (0.5%).
Children on ART experienced good immunologic
recovery, with median CD4+ T-cell percentage increasing to 28.9% (IQR: 22.6, 37.2), 32.4% (IQR: 25.1, 39.1),
and 34.2% (IQR: 30.6, 38.7) 6, 12 and 24 months after
ART initiation, respectively.

Height-for-age z-scores after ART initiation

For HAZ, 152 children were included in the analysis, of
whom 4 (2.6%) died and 4 (2.6%) were lost to follow-up
after ART initiation. A linear increase in HAZ was
observed throughout treatment and mean HAZ
increased from -3.5 at treatment initiation to -3.1, -2.6,
-2.5, and -2.1 at 6, 12, 18 and 24 months on ART,
respectively (Figure 1B). Consequently the proportion of
stunted children decreased from 71.6% at treatment
initiation to 80.5%, 66.7%, 60.5%, and 46.4% at 6, 12, 18
and 24 months on ART, respectively. Results of the

Weight-for-age z-scores after ART initiation

For WAZ, 128 children younger than 10 years were
included in the analysis, of whom 4 (3.1%) died and 4
(3.1%) were lost to follow-up after ART initiation. WAZ
increased during the first 6 months of treatment and
then stabilized. Mean WAZ increased from -2.4 at

-0.5

A

B

-1.5

-2

-1

-2.5
HAZ

WAZ

-1.5
-2

-3

-3.5

-2.5

-4

-3

-4.5
0

3

6
9
12 15 18 21
Months since ART initiation

24

0

3

6
9
12
15
18
Months since ART initiation

21

24

0

3

6

12

18

24

0

3

6

12

18

24

N

119

88

73

51

34

20

N

74

95

82

60

43

28

Mean

-3.5

-3.6

-3.1

-2.6

-2.5

-2.1

---

0.4

1.0

1.3

---

---

71.6

79.0

80.5

66.7

60.5

46.4

-2.4

-1.6

-1.3

-1.5

-1.4

-1.7

Mean

Mean change *

---

0.6

0.8

1.0

1.5

1.1

Mean change *

% underweight

59.7

34.1

28.8

35.3

26.5

45.0

% stunted

Figure 1 Mean (95% CI) weight-for-age (A) and height-for-age (B) z-scores by time since ART initiation. *sample sizes are smaller due to
missing data at ART initiation.
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Table 2 Results of the longitudinal data analysis for WAZ and HAZ after ART initiation
Weight for age z-scoresa
Coefficient (SE)

p-value/p-value interaction

0-6 months

0.12 (0.02)

<0.0001

>6 months

-0.003 (0.012)

0.81

0.12 (0.02)
0.003 (0.01)

<0.0001
0.72

Height for age z-scores
Coefficient (SE)

p-value/p-value interaction

0.053 (0.012)

<0.0001

0.10 (0.01)

<0.0001

Crude model
Time (per month) on ART

Adjusted model
Time (per month) on ART
0-6 months
>6 months
Female
Severe immunodeficiencyb,

c

0.48 (0.21)

0.02

0.60 (0.29)

0.04

-0.35 (0.21)

0.09

-0.55 (0.29)

0.06

Age (years)c
0-1.9

ref

2-4.9

-0.55 (0.26)

0.04

0.49 (0.41)

0.23

≥5

-0.52 (0.27)

0.05

1.16 (0.36)

0.001

-0.70 (0.29)

0.02
-1.68 (0.31)

<0.0001

Double orphanc
Underweightc

ref

Stratified by WAZ at ART initiationd:
WAZ ≥-2 (ref)
0-6 months (per month)

0.04 (0.02)

0.08

>6 months (per month)

0.04 (0.01)

0.005

0-6 months (per month)

0.19 (0.03)

<0.0001/<0.0001

>6 months (per month)
Stratified by age (years) at ART initiationd:
0-1.9 (ref): time (per month)

-0.01 (0.01)

0.21/0.003

WAZ <-2 (underweight)

0.15 (0.025)

<0.0001

2-4.9: time (per month)

0.11 (0.020)

<0.0001/0.18

≥5: time (per month)

0.049 (0.014)

<0.0001/<0.0001

WAZ: weight for age z-score; HAZ: height for age z-score; SE: standard error; ART: antiretroviral treatment.
a
among children < 10 years of age.
b
defined by age according to WHO 2006 guidelines.
c
measured at ART initiation.
d
WAZ model adjusted for sex, double orphan status, severe immunodeficiency and age at ART initiation; HAZ model adjusted for sex, severe immunodeficiency
and underweight at ART initiation.

crude longitudinal model indicated that HAZ increased
by 0.053 units per month after ART initiation (Table 2).
Underweight children at ART initiation had significantly
lower HAZ, while older children and females had significantly higher HAZ throughout treatment. Severe immunodeficiency at ART initiation was marginally associated
with lower HAZ. Significant differences in the trajectories of HAZ were found only by age at ART initiation,
with children older than 5 years at initiation experiencing significantly smaller increases in HAZ per month
compared to children younger than 2 years of age.

Discussion
In this study of young HIV-infected children in rural
Zambia with good immunologic recovery on ART, both
weight and height-for-age improved after initiation of
ART. Age and undernutrition at ART initiation impacted

both WAZ and HAZ, and differences in the trajectories
of WAZ and HAZ were associated with undernutrition
and age at ART initiation, respectively.
Improvements in WAZ and HAZ among HIV-infected
children treated with ART were found in other studies
throughout sub-Saharan Africa [7-18]. The trajectories
for WAZ and HAZ after ART initiation, however, differed in this study. WAZ improved for the first 6
months and then stabilized with only minimal improvements thereafter, whereas HAZ consistently improved
over time. Similar trajectories for WAZ and HAZ were
reported in one study in South Africa [10], while other
studies found linear improvements in WAZ during the
first 24 months of treatment [11,26]. Reasons for these
differences are unknown but may be due to the higher
levels of undernutrition observed in this rural population [26]. Over half of the study population was
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underweight and three-quarters stunted at ART initiation. Differences in trajectories were found between children who were underweight and those with normal
weight, with greater weight improvements in the first 6
months for children underweight at ART initiation. A
more consistent increase was found for children with
normal weight. Consequently, it is possible that this
group of rural children experienced different trajectories
than the urban populations in previous studies.
Due to the relatively young age of the study population, the impact of age at ART initiation on both WAZ
and HAZ could be evaluated. Older age was associated
with both WAZ and HAZ at ART initiation; however,
only age impacted the trajectories for HAZ, with children older than 5 years experiencing less improvement.
In other studies, HAZ did not consistently improve,
with some studies finding no significant increases
[12,13,17]. Discrepancies in HAZ may be due to the different age compositions of the study populations, as
many studies were conducted among children with an
average age older than 5 years [21]. As more infants and
young children are diagnosed and started on ART,
further evaluation of HAZ over time will be needed.
This study was limited by the small sample size beyond
two years on ART, and the small number of children
with measures available at ART initiation (Figure 1).The
role of food supplementation in achieving weight and
height gains in this study is unknown, as the criteria used
for eligibility were not consistent across clinic staff and
children did not receive supplements at every visit. In
addition, no information was collected on the child’s diet
or on comorbidities and therefore the contribution of
these factors to growth could not be assessed.

Conclusions
This study demonstrated that rural Zambian children
experienced significant improvements in both weight
and height after starting ART. However, even after two
years of ART approximately 25% and 50% of children
remained underweight and stunted, higher than
observed among HIV-negative children in the same
region [27]. Consequently, successful treatment with
ART was not able to fully reverse the effects of HIV on
growth. Partnerships between HIV treatment and nutrition programs should be explored so that children
receive an integrated care and treatment approach that
includes nutritional support. Further evaluation of the
impact of food supplementation on growth after ART
initiation is needed.
List of Abbreviations
3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; AZT: zidovudine;
D4T: stavudine; EFV: efavirenz; HAZ: height-for-age Z-score; IQR: interquartile
range; NVP: nevirapine; PMTCT: prevention of mother-to-child transmission;
SE: standard error; WAZ: weight-for-age Z-score.
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